Clinical trial NCT06659627: Interventions Against Fatigue in Patients with Myasthenia Gravis
Official title: Fatigue Improvement Through Aerobic Exercise and Cognitive Behavioural Therapy in Patients with Myasthenia Gravis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Myasthenia Gravis
Fatigue
Keywords: Myasthenia Gravis
Fatigue
Aerobic Exercise Therapy
Cognitive Behavioural Therapy
Lead sponsor: Leiden University Medical Center
Sponsor class: OTHER
First posted: 2024-10-26
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Three intervention groups
Primary purpose: TREATMENT

Brief summary: A prospective assessor-blinded randomized clinical trial investigating the effect of aerobic exercise therapy or cognitive behavioural therapy on fatigue in patients with myasthenia gravis.

Detailed description: This study will be a prospective assessor-blinded randomized controlled trial comparing AET and CBT with usual care (UC). For an individual participant, the overall study duration will be 52 weeks with a total intervention duration of 16 weeks. After 32 and 52 weeks the investigators will analyse the data from the activity tracker and approach each participant to digitally complete a total of three questionnaires. After 32 weeks the researchers will be unblinded and the study will proceed as an open-label extension study.

After signing the informed consent form, an activity tracker (Withings Pulse HR) will be provided to all participants. After a four week observation period to evaluate the baseline levels of daily activity, participants will visit the LUMC for baseline measurements and a blood test. After obtaining these baseline characteristics, all participants will be randomly assigned to either AET, CBT or UC.

Participants in the AET group start with an intake meeting with a physical therapist. AET will consist of three weekly sessions of aerobic workouts on a bicycle ergometer for a period of 16 weeks. The first training session will be supervised by an experienced physical therapist at the LUMC. Subsequently, participants will perform the remaining workouts at home. One session per week will be carried out independently at home. The other two sessions will be digitally supervised via a digital connection by students, who will be trained and supervised by an experienced physical therapist. During the intervention, training intensity will be adjusted based on the participant's rate of perceived exertion (Borg Rating of Perceived Exertion (RPE) scale). During each session, the participant is also able to adjust the wattage of that specific training. Training activity and execution will be monitored remotely using the bicycle ergometer and the activity tracker. Adherence and reasons for possible non-adherence will be monitored by the students. Outcome measures will be collected on follow-up immediately after the 16-week intervention.

Participants in the CBT group start with an online intake meeting with a psychologist. The entire CBT program will be followed digitally through an online platform and will span 12-16 weeks. The program will be tailored to the individual participants' needs and preferences. Every week or every two weeks, the psychologist provides feedback on the finished sessions and gives new assignments. If necessary, the psychologist will contact a participant by phone for additional support. Outcome measures will be collected on follow-up immediately after the 16-week intervention.

The outcome measures of the participants in the UC group are obtained after the four week observation period and after 20 weeks follow-up. Participants are not restricted in their activities, but will be instructed not to start a new exercise or cognitive behavioural program. Chronic physical therapy and psychological counselling in the context of usual care are allowed to continue. After the 32-week follow-up, the participants in the UC group have the option to follow a modified version of the AET or CBT interventions without supervision.

Participants will be given the option to undergo a quantitative muscle MRI of the upper legs. The MRI is additional and not mandatory to participate in the study. The investigators will include a maximum of 10 participants per group. Participants will undergo the MRI twice: before intervention at baseline and after intervention at 20 weeks follow-up.

Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years
2. A clinical diagnosis of myasthenia gravis (ocular or generalized) with the typical fluctuating muscle weakness and at least one of the following:

   * a positive serologic test for AChR or MuSK antibodies;
   * an abnormal electrodiagnostic test: repetitive nerve stimulation (RNS) or single-fiber electromyography (SFEMG).
3. The diagnosis of MG was made at least a year ago and the MG is stable, as determined by the treating neurologist.
4. Patients who use the following medication: prednisone, intravenous immunoglobulin (IVIg), complement inhibitor (e.g. Eculizumab), neonatal Fc receptor (FcRn) inhibitor (e.g. Efgartigimod) have been on a stable dosing regimen for at least one month.
5. MGFA Clinical Classification of disease severity I-IV.
6. Clinically relevant fatigue (a score ≥ 35 on the CIS-fatigue).
7. Ability to walk and exercise.
8. Ability to understand the requirements of the study and provide written informed consent.

Exclusion Criteria:

1. The patient is unable to fill out the study questionnaires or be interviewed in Dutch, or is unable to undergo the tests needed for the study, or is unable to give informed consent for participation in the study.
2. The patient is unable to use the activity tracker and digital infrastructure provided.
3. Co-morbidity interfering with AET or affecting exercise response and exercise capacity, including severe cardiopulmonary co-morbidity, as assessed by the investigator.
4. Co-morbidity interfering with CBT, a clinical diagnosis of depression or a score ≥12 on the Hospital Anxiety and Depression Scale (HADS), as assessed by the investigator.
5. Use of beta blockers.
6. The patient is already engaged in strenuous exercise more than twice a week.
7. The patient is already undergoing cognitive behavioural therapy.
8. Pregnancy or intention to become pregnant during the study.

Exclusion Criterion for muscle MRI 1. Inability to undergo MRI.

- In case of uncertainty about the MRI-contraindications, the MR-safety commission of the Radiology department will decide whether this subject can be included in the study or not.

Primary outcomes:
measure: A change in CIS-fatigue in the AET and CBT group, compared to UC, before and after intervention.
timeFrame: Assessed after 4 weeks and 20 weeks.
Secondary outcomes:
measure: A change in CIS-fatigue in the AET group compared to the CBT group before and after intervention and during follow-up.
timeFrame: Assessed after 20 weeks and 32 weeks.
measure: A sustained change in CIS-fatigue after AET or CBT intervention at 32 weeks (12 weeks post-intervention).
timeFrame: Assessed after 32 weeks.
measure: A long term change in CIS-fatigue after AET or CBT intervention at 52 weeks.
timeFrame: Assessed after 52 weeks.
measure: The number of completed AET or CBT sessions to investigate participants' compliance with a 16 week AET or CBT program.
timeFrame: Assessed after 20 weeks.
measure: A change in the use of MG medication before and after AET or CBT intervention, compared to usual care.
timeFrame: Assessed after 20 weeks and 32 weeks.
measure: A change in MG Quality of Life 15-item (MG-QoL 15r) Scale after AET or CBT intervention compared to usual care.
timeFrame: Assessed after 4 weeks, 20 weeks, 32 weeks and 52 weeks.
measure: A clinically relevant change in MG Activities of Daily Living (MG-ADL) Scale after AET or CBT intervention compared to usual care.
timeFrame: Assessed after 4 weeks and 20 weeks.
measure: A clinically relevant change in Quantitative MG (QMG) Scale after AET or CBT intervention compared to usual care
timeFrame: Assessed after 4 weeks and 20 weeks.
measure: Changes in amount of weekly vigorous intensity physical activity, as measured by the number of minutes per week that the heart rate reaches at least 70% of maximum heart rate after AET or CBT intervention compared to usual care.
timeFrame: Assessed after 4 weeks, 20 weeks, 32 weeks and 52 weeks.
measure: A change in cardiorespiratory fitness (CRF) after AET or CBT intervention compared to usual care.
timeFrame: Assessed after 4 weeks and 20 weeks.
measure: A change in CIS-activity after AET or CBT intervention compared to usual care.
timeFrame: Assessed after 4 weeks, 20 weeks, 32 weeks and 52 weeks.
measure: A change in Hospital Anxiety and Depression Scale (HADS) after AET or CBT intervention compared to usual care.
timeFrame: Assessed on day 1, after 4 weeks and 20 weeks.
measure: A change in Visual Analogue Scale (VAS-pain) after AET or CBT intervention compared to usual care.
timeFrame: Assessed after 4 weeks and 20 weeks.
measure: A change in Pittsburgh Sleep Quality Index (PSQI) after AET or CBT intervention compared to usual care.
timeFrame: Assessed after 4 weeks and 20 weeks.
measure: A change in the social interaction subscale of the Sickness Impact Profile (SIP) after AET or CBT intervention compared to usual care.
timeFrame: Assessed after 4 weeks and 20 weeks.
measure: A change in EQ-5D-5L after AET or CBT intervention compared to usual care.
timeFrame: Assessed on day 1, after 4 weeks, 20 weeks, 32 weeks and 52 weeks.
measure: Changes in the relation of fatigue with CRP serum levels at baseline and after AET or CBT intervention compared to usual care.
timeFrame: Assessed after 4 weeks and 20 weeks.
measure: Changes in the relation of fatigue with AChR antibody serum levels at baseline and after AET or CBT intervention compared to usual care.
timeFrame: Assessed after 4 weeks and 20 weeks.
measure: Changes in the relation of fatigue with muscle MRI parameters at baseline and after AET or CBT intervention compared to usual care.
timeFrame: Assessed after 4 weeks and 20 weeks.
measure: A change in International Physical Activity Questionnaire - Short Form (IPAQ-SF) after AET or CBT intervention compared to usual care.
timeFrame: Assessed on day 1, after 4 weeks and 20 weeks.
measure: Changes in the relation of fatigue with MuSK antibody serum levels at baseline and after AET or CBT intervention compared to usual care.
timeFrame: Assessed after 4 weeks and 20 weeks.
Other outcomes:
Locations:
city: Leiden
country: Netherlands
facility: Leiden University Medical Center
state: South-Holland
Study officials:
affiliation: Leiden University Medical Center
name: Martijn R. Tannemaat, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: